高血压治疗用药-依普利酮

Eplerenone (Planep) is a highly selective aldoketone receptor antagonist. Its mechanism of action is to competitively inhibit the binding of aldosterone to mineralocorticoid receptors, and antagonize the binding of aldosterone to mineralocorticoid receptors to exert its blood pressure lowering effect. Approved for clinical use by the State Food and Drug Administration in 2002, pure eplerenone (Planep) is a white or off-white crystal. It has a stronger antagonism to aldosterone than spironolactone, and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. It has fewer adverse reactions and good tolerance. It is a good alternative drug to spironolactone.

Eplerenone (Planep) was developed by Pfizer/Pharmacia. Eplerenone (Planep) has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Its outstanding advantage is that for severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone (Planep) can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. For patients with severe heart failure and myocardial infarction, eplerenone (Planep) combined with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve quality of life and reduce mortality.  

Relevant clinical trials have shown that the treatment of heart failure after acute myocardial infarction with eplerenone (Planep) in combination with standard treatment drugs can reduce the total mortality rate in the treatment group by 15%; eplerenone (Planep) is as effective as enalapril in reversing left ventricular hypertrophy and hypertension, has fewer cough side effects, and the combined effect is more obvious; eplerenone (Planep) has fewer adverse reactions, and except for the adverse reactions of elevated blood potassium, other adverse reactions are no different from the placebo group; there are almost no sex hormone-related side effects of spironolactone.